CL2020000632A1 - Composición y método para el tratamiento del autismo. - Google Patents

Composición y método para el tratamiento del autismo.

Info

Publication number
CL2020000632A1
CL2020000632A1 CL2020000632A CL2020000632A CL2020000632A1 CL 2020000632 A1 CL2020000632 A1 CL 2020000632A1 CL 2020000632 A CL2020000632 A CL 2020000632A CL 2020000632 A CL2020000632 A CL 2020000632A CL 2020000632 A1 CL2020000632 A1 CL 2020000632A1
Authority
CL
Chile
Prior art keywords
autism
treatment
composition
tetrahidrocannabinol
cbd
Prior art date
Application number
CL2020000632A
Other languages
English (en)
Inventor
Harry Karelis
Original Assignee
Zelda Therapeutics Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2017903766A external-priority patent/AU2017903766A0/en
Application filed by Zelda Therapeutics Operations Pty Ltd filed Critical Zelda Therapeutics Operations Pty Ltd
Publication of CL2020000632A1 publication Critical patent/CL2020000632A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

LA INVENCIÓN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN EL CANNABIDIOL (CBD) Y EL Δ9 TETRAHIDROCANNABINOL (THC), Y SU USO EN EL TRATAMIENTO DEL AUTISMO. EL INVENTO TAMBIÉN SE RELACIONA CON MÉTODOS PARA EL TRATAMIENTO DEL AUTISMO.
CL2020000632A 2017-09-15 2020-03-11 Composición y método para el tratamiento del autismo. CL2020000632A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2017903766A AU2017903766A0 (en) 2017-09-15 Composition and method for treating autism
AU2018900276 2018-01-18

Publications (1)

Publication Number Publication Date
CL2020000632A1 true CL2020000632A1 (es) 2020-08-21

Family

ID=63831830

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020000632A CL2020000632A1 (es) 2017-09-15 2020-03-11 Composición y método para el tratamiento del autismo.

Country Status (10)

Country Link
US (2) US20200276155A1 (es)
EP (1) EP3681525A4 (es)
JP (1) JP2021500312A (es)
CN (1) CN111263638A (es)
AU (2) AU2018333282A1 (es)
CA (1) CA3075122A1 (es)
CL (1) CL2020000632A1 (es)
IL (1) IL273278A (es)
SG (1) SG11202002169TA (es)
WO (1) WO2019051560A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190035791A (ko) 2016-08-03 2019-04-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
AU2018286647B2 (en) 2017-06-19 2024-03-28 Zelira Therapeutics Operations Pty Ltd Sleep disorder compositions and treatments thereof
US12582664B2 (en) 2017-09-28 2026-03-24 Harmony Biosciences Management, Inc. Treatment of fragile x syndrome with cannabidiol
MX2020003606A (es) 2017-09-28 2020-10-28 Zynerba Pharmaceuticals Inc Tratamiento del sindrome del cromosoma x fragil con canabidiol.
CA3089994A1 (en) 2018-01-31 2019-08-08 Canopy Holdings, LLC Hemp powder
US11946016B2 (en) 2018-06-14 2024-04-02 Biosoma B.V. Process for the extraction of oil-soluble components from plant material
CA3103504A1 (en) * 2018-06-15 2019-12-19 CannPal Animal Therapeutics Limited Cannabinoid composition and methods of treatment using the same
CA3119729A1 (en) 2018-10-10 2020-04-16 Treehouse Biotech, Inc. Synthesis of cannabigerol
MX2021007076A (es) 2018-12-14 2021-08-11 Zynerba Pharmaceuticals Inc Tratamiento para el sindrome de supresion del 22q11.2 con cannabidiol.
CA3129535A1 (en) * 2019-03-07 2020-09-10 Oludare ODUMOSU Formulations for treating cluster symptoms associated with autism spectrum disorder
IT201900014901A1 (it) * 2019-08-21 2021-02-21 Energicamente S R L Metodo per la preparazione di olio di cannabis
WO2021077108A1 (en) * 2019-10-18 2021-04-22 The Children's Hospital Of Philadelphia Method of treating autism
KR20230016003A (ko) * 2020-05-26 2023-01-31 지네르바 파마슈티컬스, 인코포레이티드 칸나비디올을 사용하는 자폐 스펙트럼 장애의 치료
MX2023006551A (es) * 2020-12-03 2023-08-17 Zynerba Pharmaceuticals Inc Tratamiento de las convulsiones refractarias.
CN116782891A (zh) * 2020-12-03 2023-09-19 Zyne制药公司 大麻二酚对难治性癫痫发作的治疗
ES2962999T3 (es) 2021-07-30 2024-03-22 Cannamedical Pharma Gmbh Parche transmucoso que comprende un cannabinoide y/o un opiáceo
AU2021107253A4 (en) * 2021-08-24 2021-12-09 Cymra Life Sciences Limited A composition and uses thereof
IL311852A (en) * 2021-10-11 2024-05-01 Neurotech Int Ltd Preparations and methods for the treatment of neurological disorders
WO2023060302A1 (en) * 2021-10-11 2023-04-20 Neurotech International Ltd Compositions and methods for treating neurological disorders with combination products
CN118119397A (zh) * 2021-10-11 2024-05-31 神经科技国际有限公司 用于治疗神经病症的组合物和方法
WO2023140834A1 (en) * 2022-01-19 2023-07-27 Delmarva Hemp Llc Method for solvent-free extraction and concentration of full spectrum of cannabinoids in a carrier oil
WO2024160792A1 (en) 2023-01-30 2024-08-08 Cannamedical Pharma Gmbh Improved transmucosal patch comprising a cannabinoid and/or an opioid
WO2025038586A1 (en) * 2023-08-11 2025-02-20 Defloria Llc Composition of cannabinoid extract of cw1as1 for the treatment of autism and associated symptoms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10051427C1 (de) * 2000-10-17 2002-06-13 Adam Mueller Verfahren zur Herstellung eines Tetrahydrocannabinol- und Cannabidiol-haltigen Extraktes aus Cannabis-Pflanzenmaterial sowie Cannabis-Extrakte
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
PT1542657E (pt) * 2002-08-14 2012-02-29 Gw Pharma Ltd Formulações líquidas canabinóides para administração pela mucosa
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
CA3135893C (en) * 2014-10-21 2023-11-14 United Cannabis Corp. Cannabis extracts and methods of preparing and using same
ES2938560T5 (en) * 2015-05-28 2026-04-24 Fresh Cut Dev Llc Stable cannabinoid formulations
WO2017151980A1 (en) * 2016-03-03 2017-09-08 Segreti Louis M Cannabis-based bioactive formulations and methods for use thereof
WO2018023166A1 (en) * 2016-08-03 2018-02-08 Zelda Therapeutics Operations Pty Ltd Cannabis composition
CA3046638A1 (en) * 2016-11-11 2018-05-17 Bennes, Inc. Formulations for efficient delivery of cannabinoids

Also Published As

Publication number Publication date
AU2018101357A4 (en) 2018-10-18
SG11202002169TA (en) 2020-04-29
AU2018333282A1 (en) 2020-03-19
EP3681525A4 (en) 2020-09-02
EP3681525A1 (en) 2020-07-22
IL273278A (en) 2020-04-30
US20200276155A1 (en) 2020-09-03
CA3075122A1 (en) 2019-03-21
US20230364052A1 (en) 2023-11-16
AU2018101357B4 (en) 2022-03-17
CN111263638A (zh) 2020-06-09
WO2019051560A1 (en) 2019-03-21
JP2021500312A (ja) 2021-01-07

Similar Documents

Publication Publication Date Title
CL2020003368A1 (es) Composicion y metodo para tratar el dolor
CO2019001043A2 (es) Composición de cannabis
PE20200338A1 (es) Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil
BR112019012354A2 (pt) anticorpos apenas de cadeia pesada anti-bcma
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
EA201791299A1 (ru) Микроинкапсулированные композиции каннабиноидов
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
CL2016001609A1 (es) Composiciones farmacéuticas que comprenden azd9291.
MX2017016345A (es) Proteinas de fusion para inhibir la angiogenesis.
CL2016000063A1 (es) Nuevos derivados de indolizina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
EA201991447A1 (ru) Снижение вязкости фармацевтических составов
MX378687B (es) Formulacion de vitamina soluble en grasa.
CO2017002472A2 (es) Formulación de acetato de abiraterona
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
CL2020003373A1 (es) Composición y método de ahorro de opiáceos
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
MX2016012784A (es) Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones.
DOP2016000007A (es) Pirazolpiridinas sustituidas
CR20150653A (es) Compuestos nuevos para el tratamiento del cáncer
CR20170090A (es) Derivados de terahidroquinolina como inhibidores del bromodominio
DOP2017000085A (es) Derivados estabilizados de adrenomedulina y uso de los mismos
CO2019000604A2 (es) Composición vaginal que comprende una combinación de estrógeno y vitamina d
CL2017000560A1 (es) Fórmula que incluye glicopirrolato, método y sistema